Walder Wyss advised Amag Leasing through placement of two senior green bond tranches in the amounting CHF 280,000,000. The bonds will be listed on the SIX Swiss Exchange. UBS Investment Bank, Zürcher Kantonalbank and
Tags :Walder Wyss
Walder Wyss advised ExcellGene and Magellan Biologics & Consulting Global, on the sale of a majority stake to private equity healthcare specialist Archimed. The deal sets to create a group covering gene transfer, cell line
Walder Wyss advised GlobalLogic, a US subsidiary of the Japanese Hitachi Group, and its lead legal advisor, the German law firm, on the acquisition of the Synvert Group from private equity fund Maxburg. The parties
Walder Wyss advised Fielmann Group and tele-ophthalmology platform Ocumeda, as the the first agreed to sell a 10% stake in Ocumenda to Zeiss Vision Care. The deal implied a total company valuation of EUR 100m, with
Walder Wyss advised Bobst Group throughout the issuance of CHF 200m senior unsecured bonds maturing in 2030 and with 2.05% coupon. The bonds in question are set to debut on the SIX Swiss Exchange. UBS, BNP Paribas,
Walder Wyss advised Groupe E on a CHF 250m bond issuance. The transaction encompasses a CHF 100m 4-year tranche with a fixed coupon of 0.750% and a CHF 150m 10-year tranche with a fixed coupon
SMG – a joint venture between TX Group, Ringier, Mobiliar and General Atlantic – makes its debut today, September 19, on the SIX Swiss Exchange. The Zurich-based group trades under the ticker symbol “SMG”, pricing at CHF 46 per
Walder Wyss advised Helvetia Schweizerische Versicherungsgesellschaft and Helvetia Holding on a new CHF 300m syndicated revolving credit facility. Moreover – in connection with the deal – Niederer Kraft Frey (NKF) represented Deutsche Bank AG as coordinator and
Walder Wyss advised dsm-firmenich on the sale of Pentapharm and its Brazilian sister company Pentapharm do Brasil Comércio e Exportação to Orlando Capital V. Founded in 1948 and headquartered in Aesch, Pentapharm is a
Walder Wyss advised the Dec Group – a specialist in high-containment processing technologies for the pharmaceutical, chemical, and specialty industries – and its existing shareholders, throughout completion of a financial partnership with ICG, an alternative asset manager
